)
Edge10 Jul 2026
Inside Take-Two: The Grand Anticipation
The story of how Take-Two Interactive built the empire behind Grand Theft Auto, Red Dead Redemption, and one of gaming's largest mobile portfolios.
Decoy Therapeutics
Decoy Therapeutics (DCOY) investor relations material
Decoy Therapeutics Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary10 Jul, 2026
Company overview and business model
Pre-clinical stage biotechnology company developing peptide conjugate therapeutics using a proprietary AI/ML-driven IMP3ACT™ platform targeting infectious diseases and oncology.
Pipeline includes Designable Multi-Antivirals (D-MAV) for respiratory viruses and two legacy small molecule clinical candidates.
No approved products or revenue from product sales to date.
Recent merger with Legacy Decoy and name change effective January 8, 2026.
Financial performance and metrics
Recurring operating losses since inception; no product sales revenue.
$3.5 million raised in June 2026 private placement; cash expected to fund operations only into late 2026.
Substantial doubt about ability to continue as a going concern per auditor and management.
Use of proceeds and capital allocation
No proceeds from resale of shares by selling stockholders; proceeds from any cash exercise of warrants will be used for working capital and general corporate purposes.
If all warrants are exercised for cash, potential gross proceeds of approximately $19.1 million.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Decoy Therapeutics
- Equity line offering raises up to $5M, with major dilution and liquidity risks for shareholders.DCOY
Registration filing15 Jun 2026 - Shareholders to vote virtually on directors, executive pay, and auditor ratification for 2026.DCOYProxy filing4 Jun 2026
- Annual meeting to vote on directors, executive pay, and auditor, with strong governance and oversight.DCOYProxy filing4 Jun 2026
- Q1 2026 net loss rose to $2.22M as R&D spending surged post-merger; cash funds last into late 2026.DCOYQ1 20268 May 2026
- AI-driven multi-antivirals advance toward clinical trials with major milestones ahead.DCOYStatus update13 Apr 2026
- 2025 net loss rose to $12.5M, with cash runway into late 2026 but going concern risk persists.DCOYQ4 202531 Mar 2026
- Vote on equity plan and reverse split to support Nasdaq listing after merger.DCOYProxy Filing9 Jan 2026
- Key votes on equity plan and reverse split aim to secure Nasdaq listing after Decoy merger.DCOYProxy Filing29 Dec 2025
- Proxy statement supplement details annual meeting adjournment and proxy solicitation engagement.DCOYProxy Filing19 Dec 2025
Next Decoy Therapeutics earnings date
Q2 20265 Aug, 2026
Decoy Therapeutics
Next Decoy Therapeutics earnings date
Q2 20265 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage